Fosun International Limited (HK:0656)
:0656
Top Page
Fosun International
(0656)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$4.00
▼(-7.62% Downside)
Action:ReiteratedDate:11/05/25
The overall stock score is primarily influenced by significant financial challenges, including a highly leveraged balance sheet and weak cash flow. Technical indicators further suggest bearish momentum, while valuation metrics indicate potential overvaluation. These factors collectively contribute to a low overall score.
Positive Factors
Diversified business model
A multi-segment model across health, consumer lifestyle, insurance/asset management and manufacturing spreads revenue risk and creates multiple, complementary cash-generation channels. This structural diversification supports resilience across economic cycles and enables cross-selling and capital allocation flexibility.
Negative Factors
High financial leverage
Substantial leverage reduces financial flexibility and raises refinancing and interest-rate risks. High debt levels constrain capital allocation, increase vulnerability to market volatility, and can force asset sales or dilute shareholders if sustained, weakening long-term strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified business model
A multi-segment model across health, consumer lifestyle, insurance/asset management and manufacturing spreads revenue risk and creates multiple, complementary cash-generation channels. This structural diversification supports resilience across economic cycles and enables cross-selling and capital allocation flexibility.
Read all positive factors
Fosun International (0656) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$35.01B
Dividend Yield0.44%
Average Volume (3M)7.09M
Price to Earnings (P/E)13.1
Beta (1Y)1.05
Revenue Growth-8.93%
EPS Growth-698.78%
CountryHK
Employees104,000
SectorIndustrials
Sector Strength72
IndustryConglomerates
Share Statistics
EPS (TTM)-3.23
Shares Outstanding8,180,232,000
10 Day Avg. Volume5,394,621
30 Day Avg. Volume7,085,908
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.29
Price to Sales (P/S)0.18
P/FCF Ratio2.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.32Price Target Upside45.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.21
Revenue Forecast (FY)HK$175.64B
Fosun International Business Overview & Revenue Model
Company Description
Fosun International Limited operates in health, happiness, wealth, and intelligent manufacturing sectors in Mainland China, Portugal, and internationally. It operates in five segments: Health, Happiness, Insurance, Asset Management, and Intelligen...
How the Company Makes Money
Fosun International generates revenue through various key streams. Primarily, it earns income from its healthcare segment, which includes pharmaceutical manufacturing, health management services, and medical devices. The insurance sector contribut...
Fosun International Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 181.59B | 192.14B | 198.20B | 182.43B | 161.29B | 136.74B |
| Gross Profit | 49.65B | 51.60B | 50.80B | 47.31B | 55.65B | 50.59B |
| EBITDA | 429.15M | 329.02M | 30.50B | 1.02B | 4.05B | 5.02B |
| Net Income | -4.41B | -4.35B | 1.38B | -831.80M | 10.08B | 8.00B |
Balance Sheet | ||||||
| Total Assets | 735.69B | 796.53B | 808.39B | 806.38B | 806.28B | 767.72B |
| Cash, Cash Equivalents and Short-Term Investments | 111.54B | 133.09B | 133.27B | 150.38B | 166.93B | 166.95B |
| Total Debt | 222.11B | 241.86B | 233.57B | 245.92B | 257.87B | 250.87B |
| Total Liabilities | 538.35B | 598.99B | 599.81B | 607.30B | 603.16B | 574.64B |
| Stockholders Equity | 118.14B | 118.10B | 124.94B | 120.73B | 131.00B | 127.81B |
Cash Flow | ||||||
| Free Cash Flow | 13.20B | 15.61B | -3.35B | -5.45B | -9.64B | 2.73B |
| Operating Cash Flow | 16.24B | 26.88B | 9.82B | 1.76B | -3.32B | 8.89B |
| Investing Cash Flow | -2.72B | -126.97M | 17.59B | 35.58B | -536.96M | 612.52M |
| Financing Cash Flow | -18.06B | -14.27B | -39.67B | -38.12B | -3.66B | 2.29B |
Fosun International Technical Analysis
Positive
4.33
Price Trends
3.96
Positive
4.33
Negative
4.77
Negative
Market Momentum
0.07
Negative
64.98
Neutral
85.73
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0656, the sentiment is Positive. The current price of 4.33 is above the 20-day moving average (MA) of 3.94, above the 50-day MA of 3.96, and below the 200-day MA of 4.77, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 64.98 is Neutral, neither overbought nor oversold. The STOCH value of 85.73 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0656.
Fosun International Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$22.12B | 2.84 | 6.12% | 5.00% | 7.45% | 11.56% | |
68 Neutral | HK$105.51B | 28.96 | 1.14% | 5.26% | 6.44% | -95.37% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
63 Neutral | HK$232.68B | 17.13 | 2.12% | 4.02% | 1.93% | -65.62% | |
62 Neutral | HK$346.76B | 5.51 | 5.53% | 5.15% | 2.45% | -0.36% | |
60 Neutral | HK$38.42B | 7.30 | 5.66% | 4.94% | ― | ― | |
42 Neutral | HK$35.01B | 13.10 | -3.73% | 0.44% | -8.93% | -698.78% |
* Industrials Sector Average
HK:0656
Fosun International
4.29
0.48
12.51%
HK:0392
Beijing Enterprises Holdings
30.54
3.73
13.91%
HK:0001
CK Hutchison Holdings
60.75
22.43
58.54%
HK:0267
CITIC
11.92
4.12
52.76%
HK:0053
Guoco Group
68.00
7.89
13.13%
HK:0019
Swire Pacific
87.50
25.29
40.65%
Fosun International Corporate Events
Fosun Unit to Take Control of Zhejiang Shangmeng Technology With RMB105 Million Capital Injection
Feb 4, 2026
Fosun International, via its indirect wholly owned unit Zhejiang Fosun Commercial Development, has agreed to inject RMB105 million in cash into Zhejiang Shangmeng Technology Co., Ltd., subscribing to newly issued registered capital and securing a ...
Fosun International Acquires Controlling Stake in Green Valley Technology
Dec 15, 2025
Fosun International, through its subsidiary Fosun Pharma Industrial, has entered into an agreement to acquire a controlling stake in Green Valley Technology. This acquisition involves purchasing an 8.6667% equity interest and subscribing to new ca...
Fosun Pharma Renews Strategic Supply Agreement with CQ Pharma Holdings
Nov 28, 2025
Fosun Pharma, a subsidiary of Fosun International, has entered into a Mutual Supply Framework Agreement with CQ Pharma Holdings, effective from January 1, 2026, to December 31, 2028. This agreement, which renews a previous arrangement, involves th...
Fosun International Announces Board Composition and Roles
Nov 27, 2025
Fosun International Limited has announced the composition of its board of directors, including executive, non-executive, and independent non-executive directors. The announcement also details the roles and committee memberships of each board membe...
Fosun International Announces Director Resignation
Nov 27, 2025
Fosun International Limited announced the resignation of Mr. Li Shupei as a non-executive director, effective November 27, 2025, due to personal work arrangements. The company expressed gratitude for Mr. Li’s contributions and confirmed ther...
Fosun Completes Major Share Disposal in HAL Privatbank
Nov 24, 2025
Fosun International Limited has completed the sale of its shares in Hauck Aufhäuser Lampe Privatbank AG through its subsidiary Bridge Fortune. The transaction, valued at approximately EUR 703 million, signifies a strategic move for Fosun, pot...
Fosun Pharma Initiates First Grant Under 2025 H Share RSU Scheme
Nov 4, 2025
Fosun Pharma has announced the first grant under its 2025 H Share RSU Scheme, reducing the number of grantees to 195 and the RSUs to 10,589,500 due to changes in eligible employees. This move is part of its strategic efforts to incentivize employe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.